(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 July 2003 (17.07.2003)

PCT

(10) International Publication Number
WO 03/057217 A1

(51) International Patent Classification[7]: A61K 31/427, 31/513, 31/7068, A61P 35/00 // (A61K 31/7068, 31:427) (A61K 31/513, 31:427)

(21) International Application Number: PCT/EP03/00232

(22) International Filing Date: 13 January 2003 (13.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/348,622	14 January 2002 (14.01.2002)	US
60/416,173	4 October 2002 (04.10.2002)	US

(71) Applicant *(for all designated States except AT, US)*: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(71) Applicant *(for AT only)*: NOVARTIS PHARMA GMBH [AT/AT]; Brunner Stasse 59, 1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: HOHNEKER, John, Arthur [US/US]; 21 Hilltop Circle, Morristown, NJ 07960 (US). MCSHEEHY, Paul, M., J. [GB/DE]; Erlenweg 11, 79540 Loerrach-Stetten (DE). ROTHERMEL, John, David [US/US]; 46 School House Road, Randolph, NJ 07869 (US).

(74) Agent: GROS, Florent; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.


(84) Designated States *(regional)*: Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/057217 A1

(54) Title: COMBINATIONS COMPRISING EPOTHILONES AND ANTI-METABOLITES



(I)

(57) Abstract: Disclosed is a combination which comprises (a) an antineoplastic antimetabolite and (b) an epothilone derivative of formula (I), wherein A represents O or NR_N, wherein R_N is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino, aminomethyl or methylthio, and Z is O or a bond, and optionally at least one pharmaceutically acceptable carrier and/or, optionally, a standard anti-diarrheal, for simultaneous, separate or sequential use, in particular for the treatment of a proliferative disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal.